Press release
Uveal Melanoma Pipeline, Clinical Trials Assessment, NDA Approvals 2023 (Updated) | Novartis Pharmaceuticals, Foghorn Therapeutics, TriSalus Life Sciences, Inc., Bristol Myers Squibb, and others
Uveal Melanoma Pipeline
In the Uveal Melanoma Pipeline Report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, Uveal Melanoma NDA approvals (if any), and product development activities comprising the technology, Intraocular(Uveal) melanoma collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
To explore more information on the latest breakthroughs in the Uveal Melanoma pipeline treatment landscape of the report, click here @ Uveal Melanoma Pipeline- https://www.delveinsight.com/report-store/uveal-melanoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Key Takeaways from the Uveal Melanoma Pipeline Report
• DelveInsight's Uveal Melanoma Pipeline analysis depicts a robust space with 25+ active players working to develop 30+ pipeline treatment therapies.
• The leading Uveal Melanoma Companies working in the market include Novartis Pharmaceuticals, Foghorn Therapeutics, TriSalus Life Sciences, Inc., Bristol Myers Squibb, and others.
• Promising Uveal Melanoma Pipeline Therapies in the various stages of development include AEB071, FHD286, Dacarbazine, Ipilimumab, Pembrolizumab, DYP688, IMCgp100, SD-101, BVD-523, Marqibo® (vincristine sulfate liposomes injection), ICON-1, and others.
• On March 2023, Foghom Therapeutics Inc announced a study of phase 1 clinical trials for FHD-286. This Phase 1, multicenter, open-label, dose escalation and expansion study is designed to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary clinical activity of FHD-286 oral monotherapy in subjects with metastatic Uveal Melanoma (UM).
• On March 2023, Immunocore Ltd announced a study of phase 2 clinical trials for Dacarbazine. To evaluate the overall survival of HLA-A*0201 positive adult patients with previously untreated advanced UM receiving IMCgp100 compared to Investigator's Choice of dacarbazine, ipilimumab, or pembrolizumab.
• On March 2023, Novartis Pharmaceuticals announced a study of phase 1 & 2 for DYP688. This is a FIH, phase I/II, open label, multi-center study of DYP688 as a single agent. The purpose of this study is to characterize the safety, tolerability, and anti-tumor activity of DYP688 as a single agent in patients with metastatic uveal melanoma (MUM) and other melanomas harboring GNAQ/11 mutations.
Uveal Melanoma Overview
Uveal melanoma is the most common primary intraocular malignancy in adults. Intraocular is a disease in which malignant cells form in the tissues of the eye. Signs of intraocular melanoma include blurred vision or a dark spot on the iris. While development of uveal melanoma is largely considered to be a sporadic event, certain risk factors including light iris color, light skin color, ability to tan and others predispose individuals to Uveal melanoma.
To explore more information on the latest breakthroughs in the Uveal Melanoma Pipeline treatment landscape of the report, click here @ https://www.delveinsight.com/sample-request/uveal-melanoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Uveal Melanoma Emerging Drugs Profile
• BVD-523: BioMed Valley Discoveries, Inc
• AU-011: Aura Biosciences, Inc
• PAC-1: Vanquish Oncology
Uveal Melanoma Pipeline Therapeutics Assessment
There are approx. 25+ key companies which are developing the therapies for Intraocular (Uveal) melanoma. The Uveal Melanoma companies which have their Intraocular (Uveal) melanoma drug candidates in the most advanced stage, i.e. phase II include BioMed Valley Discoveries, Inc.
Request a sample and discover the recent advances in Uveal Melanoma Ongoing Clinical Trial Analysis and Medications, click here @ https://www.delveinsight.com/sample-request/uveal-melanoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Uveal Melanoma Drugs and Companies
• AEB071: Novartis Pharmaceuticals
• FHD-286: Foghorn Therapeutics Inc
• Dacarbazine: Immunocore Ltd
• DYP688: Novartis Pharmaceuticals
• IMCgp100: Immunocore Ltd
Uveal Melanoma Therapeutics Assessment
• Assessment by Stage and Product Type
• Assessment by Route of Administration
• Assessment by Stage and Route of Administration
• Assessment by Molecule Type
• Assessment by Stage and Molecule Type
Some of the Companies in the Uveal Melanoma Therapeutics Market include-
Novartis Pharmaceuticals, Foghorn Therapeutics, TriSalus Life Sciences, Inc., Bristol Myers Squibb, and others.
Dive deep into rich insights for drugs for Uveal Melanoma Pipeline, click here for Uveal Melanoma Unmet Needs and Analyst Views @ https://www.delveinsight.com/sample-request/uveal-melanoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Scope of the Uveal Melanoma Pipeline Report
• Coverage- Global
• Companies- Novartis Pharmaceuticals, Foghorn Therapeutics, TriSalus Life Sciences, Inc., Bristol Myers Squibb, and others.
• Pipeline Therapies- AEB071, FHD286, Dacarbazine, Ipilimumab, Pembrolizumab, DYP688, IMCgp100, SD-101, BVD-523, Marqibo® (vincristine sulfate liposomes injection), ICON-1, and others.
• Uveal Melanoma Pipeline Segmentation: Product Type, Molecule Type, Route of Administration
Got Queries? Find out the related information on Uveal Melanoma Mergers and acquisitions, Licensing Activities @ https://www.delveinsight.com/sample-request/uveal-melanoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Table of Content
1. Introduction
2. Executive Summary
3. Intraocular (Uveal) melanoma: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Intraocular (Uveal) melanoma - DelveInsight's Analytical Perspective
7. In-depth Commercial Assessment
8. Intraocular (Uveal) melanoma Collaboration Deals
9. Late Stage Products (Preregistration)
10. Drug Name: Company Name
11. Drug profiles in the detailed report…..
12. Mid Stage Products (Phase II)
13. BVD-523: BioMed Valley Discoveries Inc
14. Drug profiles in the detailed report…..
15. Early Stage Products (Phase I)
16. Drug Name: Company Name
17. Drug profiles in the detailed report…..
18. Preclinical Stage Products
19. Drug Name: Company name
20. Drug profiles in the detailed report…..
21. Inactive Products
22. Intraocular (Uveal) melanoma Key Companies
23. Intraocular (Uveal) melanoma Key Products
24. Intraocular (Uveal) melanoma- Unmet Needs
25. Intraocular (Uveal) melanoma- Market Drivers and Barriers
26. Intraocular (Uveal) melanoma- Future Perspectives and Conclusion
27. Intraocular (Uveal) melanoma Analyst Views
28. Intraocular (Uveal) melanoma Key Companies
29. Appendix
About Us
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: ybhardwaj@delveinsight.com
Phone: 9193216187
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Uveal Melanoma Pipeline, Clinical Trials Assessment, NDA Approvals 2023 (Updated) | Novartis Pharmaceuticals, Foghorn Therapeutics, TriSalus Life Sciences, Inc., Bristol Myers Squibb, and others here
News-ID: 3140445 • Views: …
More Releases from DelveInsight Business Research
Spinocerebellar Ataxias Pipeline 2025: Comprehensive Clinical Trials and Therapi …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Spinocerebellar Ataxias pipeline constitutes 8+ key companies continuously working towards developing 10+ Spinocerebellar Ataxias treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
"Spinocerebellar Ataxias Pipeline Insight, 2025" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Spinocerebellar Ataxias Market.
The Spinocerebellar…
Presbyopia Market to Evolve Rapidly Over the Next Decade by 2034, DelveInsight O …
The Presbyopia market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Presbyopia pipeline products will significantly revolutionize the Presbyopia market dynamics.
DelveInsight's "Presbyopia Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Presbyopia, historical and forecasted epidemiology as well as the Presbyopia market trends in the United States, EU5 (Germany, Spain, Italy, France,…
Idiopathic Pulmonary Fibrosis Market Insights Highlight Expanding Outlook Till 2 …
DelveInsight's "Idiopathic Pulmonary Fibrosis Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Idiopathic Pulmonary Fibrosis, historical and forecasted epidemiology as well as the Idiopathic Pulmonary Fibrosis market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
The latest healthcare forecast report provides an in-depth analysis of Idiopathic Pulmonary Fibrosis, offering comprehensive insights into the Idiopathic Pulmonary Fibrosis revenue trends,…
Myocardial Infarction Market Positioned for Accelerated Development Through 2034 …
DelveInsight's "Myocardial Infarction Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Myocardial Infarction, historical and forecasted epidemiology as well as the Myocardial Infarction market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
To Know in detail about the Myocardial Infarction market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Myocardial Infarction Market Forecast
https://www.delveinsight.com/sample-request/myocardial-infarction-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Some of the…
More Releases for Uveal
Metastatic Uveal Melanoma Therapeutics Market: An In-Depth Analysis
The Metastatic Uveal Melanoma Therapeutics market was valued at USD 1.23 billion in 2023 and is projected to reach approximately USD 3.00 billion by 2033, growing at an estimated CAGR of around 8.9% from 2024 to 2033.
Metastatic Uveal Melanoma Therapeutics Market Overview
The Metastatic Uveal Melanoma Therapeutics market is evolving rapidly with the emergence of novel targeted and immunotherapeutic treatments addressing this rare and aggressive cancer. Increasing research into tumor-specific pathways…
Metastatic Uveal Melanoma Therapeutics Market Future Prediction Report By 2030
𝐆𝐥𝐨𝐛𝐚𝐥 𝐦𝐞𝐭𝐚𝐬𝐭𝐚𝐭𝐢𝐜 𝐮𝐯𝐞𝐚𝐥 𝐦𝐞𝐥𝐚𝐧𝐨𝐦𝐚 𝐭𝐡𝐞𝐫𝐚𝐩𝐞𝐮𝐭𝐢𝐜𝐬 𝐦𝐚𝐫𝐤𝐞𝐭 𝐰𝐚𝐬 𝐯𝐚𝐥𝐮𝐞𝐝 𝐚𝐭 𝐚𝐩𝐩𝐫𝐨𝐱𝐢𝐦𝐚𝐭𝐞𝐥𝐲 𝐔𝐒𝐃 𝟏.𝟐𝟑 𝐛𝐢𝐥𝐥𝐢𝐨𝐧. 𝐈𝐭 𝐢𝐬 𝐩𝐫𝐨𝐣𝐞𝐜𝐭𝐞𝐝 𝐭𝐨 𝐫𝐞𝐚𝐜𝐡 𝐚𝐫𝐨𝐮𝐧𝐝 𝐔𝐒𝐃 𝟐.𝟑𝟑 𝐛𝐢𝐥𝐥𝐢𝐨𝐧 𝐛𝐲 𝟐𝟎𝟑𝟎, 𝐞𝐱𝐡𝐢𝐛𝐢𝐭𝐢𝐧𝐠 𝐚 𝐜𝐨𝐦𝐩𝐨𝐮𝐧𝐝 𝐚𝐧𝐧𝐮𝐚𝐥 𝐠𝐫𝐨𝐰𝐭𝐡 𝐫𝐚𝐭𝐞 (𝐂𝐀𝐆𝐑) 𝐨𝐟 𝟖.𝟓𝟗% 𝐝𝐮𝐫𝐢𝐧𝐠 𝐭𝐡𝐞 𝐟𝐨𝐫𝐞𝐜𝐚𝐬𝐭 𝐩𝐞𝐫𝐢𝐨𝐝 𝐟𝐫𝐨𝐦 𝟐𝟎𝟐𝟒 𝐭𝐨 𝟐𝟎𝟑𝟎.
𝐌𝐞𝐭𝐚𝐬𝐭𝐚𝐭𝐢𝐜 𝐔𝐯𝐞𝐚𝐥 𝐌𝐞𝐥𝐚𝐧𝐨𝐦𝐚 𝐓𝐡𝐞𝐫𝐚𝐩𝐞𝐮𝐭𝐢𝐜𝐬 𝐌𝐚𝐫𝐤𝐞𝐭 𝐎𝐯𝐞𝐫𝐯𝐢𝐞𝐰
The metastatic uveal melanoma therapeutics market is experiencing significant growth, driven by the increasing incidence of uveal melanoma and advancements in treatment options. Uveal…
Global Uveal Melanoma Treatment Market Will Generate Record Revenue by 2028
This Uveal Melanoma Treatment market report is the product of thorough market study and comments on important factors that influence financial decision. Here, helpful insights on customer demands are provided in order to launch the best product or service on the market. COVID-19's detrimental effects on the world economy system are also captured in this way. As a result of the pandemic, some businesses experienced considerable financial losses. Several businesses…
Uveal Melanoma Therapeutics- Clinical Trials & Results | HARMONIC PHARMA, Immuno …
Uveal melanoma is the most common primary malignant tumour of intraocular malignancy, arises from melanocytes in the iris, and ciliary body.
Download the sample report @ https://www.pharmaproff.com/request-sample/1121
The most common symptoms of uveal carcinoma include blurred vision, photopsia, visual field loss, visible tumour, pain, and metamorphopsia. The management of uveal melanoma can be divided into globe-preserving therapy or enucleation. Globe-preserving therapies can broadly classified into radiation, surgical, and laser therapy.
Get…
Uveal Melanoma Global Market Research Report 2025
Uveal Melanoma Report by Material, Application, and Geography � Global Forecast to 2022 is a professional and in-depth research report on the world's major regional market conditions, focusing on the main regions (North America, Europe and Asia-Pacific) and the main countries (United States, Germany, united Kingdom, Japan, South Korea and China).
Access more details about this report at: https://www.research2reports.com/report-medical-devices/uveal-melanoma-market/80986
The report firstly introduced the Uveal Melanoma basics: definitions, classifications, applications and…
Uveal Melanoma Market By Analysis of Major Industry Segments 2024
Global Uveal Melanom Market: Overview
Uvea is present posterior to sclera and the cornea and has three parts namely, iris, ciliary body and choroid. Uveal melanoma is referred as the cancer of the parts of eye including the iris choroid and ciliray body. It is the condition in which the tumors arise from the melanocytes residing within the uva responsible for the color of the eye. Though is a rare…
